Immunic announces publication of data from its phase 2 emphasis trial of vidofludimus calcium in relapsing-remitting multiple sclerosis in peer reviewed journal, annals of clinical and translational neurology

New york , june 15, 2022 /prnewswire/ -- immunic , inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that data from its phase 2 emphasis trial of lead asset, vidofludimus calcium (imu-838), in patients with relapsing-remitting multiple sclerosis (rrms), has been published in the peer reviewed journal, annals of clinical and translational neurology. the paper, authored by coordinating investigator, robert j.
IMUX Ratings Summary
IMUX Quant Ranking